Patrick Schafer @ CSafe Global

CSafe CEO Pat Schafer
(L-r) Bill Mitchell, chairman of PCI Pharma Services and a CSafe Global board member and Patrick Schafer, CSafe CEO.
Share this article »

CSafe Global, provider of temperature-controlled container solutions for the transport of life-enhancing pharmaceuticals and the fast-growing cell and gene market, announces that Patrick Schafer has been named as the company’s new chief executive officer.

Bill Mitchell, chairman of PCI Pharma Services and a CSafe Global board member made the announcement to CSafe Global employees at the company’s headquarters and via video conference to its more than 200 employees worldwide.

Mitchell says: “Mr. Schafer’s unmatched knowledge and understanding of the industry and the CSafe organisation, along with the exceptional rapport he’s built with the team during his 8-year tenure will help him lead CSafe to new levels of success. The entire board believes in this business and we are confident that Mr. Schafer will continue to drive growth and deliver excellent products and service to our customers.”

Schafer began his career at CSafe in 2012 as the chief financial officer and has been serving as the interim CEO since September 2019. A dual US and European citizen, Schafer has broad international experience having spent part of his career living and working in Europe.

“CSafe is an extraordinary company – one that I am honoured to have the opportunity to lead,” says Schafer. “We have the best products in the industry, the best service and support, and the best team of innovative thinkers in our space. I have no doubt CSafe will continue to be the premier provider of cold chain shipping solutions and I am thrilled to help our entire team around the world work toward our goals.”

With the executive team now in place, the company says the industry can expect to see much more from CSafe in the coming months and years. Schafer adds: “We’ve made significant additions to our team and have rapidly expanded our active container fleet. We have an unrivalled global footprint and are eager to share our world-class cell and gene solutions and our new artificial intelligence platform. We are poised to not only fullfill current customer demand, but also provide exceptional solutions well into the future.”

Be the first to comment

Leave a Reply

Your email address will not be published.


17 + 4 =